Search research articles
Contact Us
Filters
Showing results (291-300 of 304) with videos related to
Page
of 31
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 1999
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects
D J Propper, M P Saunders, A J Salisbury, et al.
Cancer Research
|
September 18, 2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
J F Robertson, R I Nicholson, N J Bundred, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 1997
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas
A Makris, T J Powles, M Dowsett, et al.
Endocrine-Related Cancer
|
August 23, 2005
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience
M Dowsett, S Johnston, L-A Martin, et al.
Breast Cancer Research and Treatment
|
February 13, 2014
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer
S Irshad, C Gillett, S E Pinder, et al.
British Journal of Cancer
|
November 30, 2006
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
J-Y Pierga, J S Reis-Filho, S J Cleator, et al.
Human Mutation
|
January 1, 1997
Screening for ESR mutations in breast and ovarian cancer patients
T I Anderson, R Wooster, K Laake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2015
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype
M Gnant, I Sestak, M Filipits, et al.
Endocrine-Related Cancer
|
August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment
J M W Gee, A Howell, W J Gullick, et al.
British Journal of Cancer
|
September 17, 2014
The AURORA initiative for metastatic breast cancer
D Zardavas, M Maetens, A Irrthum, et al.
Page
of 31
Search research articles
Search
Showing results (291-300 of 304) with videos related to
Sort By:
Page
of 31
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 1999
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects
D J Propper, M P Saunders, A J Salisbury, et al.
Cancer Research
|
September 18, 2001
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
J F Robertson, R I Nicholson, N J Bundred, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 1, 1997
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas
A Makris, T J Powles, M Dowsett, et al.
Endocrine-Related Cancer
|
August 23, 2005
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience
M Dowsett, S Johnston, L-A Martin, et al.
Breast Cancer Research and Treatment
|
February 13, 2014
Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer
S Irshad, C Gillett, S E Pinder, et al.
British Journal of Cancer
|
November 30, 2006
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
J-Y Pierga, J S Reis-Filho, S J Cleator, et al.
Human Mutation
|
January 1, 1997
Screening for ESR mutations in breast and ovarian cancer patients
T I Anderson, R Wooster, K Laake, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2015
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype
M Gnant, I Sestak, M Filipits, et al.
Endocrine-Related Cancer
|
August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment
J M W Gee, A Howell, W J Gullick, et al.
British Journal of Cancer
|
September 17, 2014
The AURORA initiative for metastatic breast cancer
D Zardavas, M Maetens, A Irrthum, et al.
Page
of 31